KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Gains from Investment Securities (2020 - 2025)

Historic Gains from Investment Securities for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to $2.4 million.

  • Recursion Pharmaceuticals' Gains from Investment Securities rose 14176.07% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$14.9 million, marking a year-over-year decrease of 28657.49%. This contributed to the annual value of -$7.6 million for FY2024, which is 12385.59% down from last year.
  • Recursion Pharmaceuticals' Gains from Investment Securities amounted to $2.4 million in Q3 2025, which was up 14176.07% from -$4.7 million recorded in Q2 2025.
  • Over the past 5 years, Recursion Pharmaceuticals' Gains from Investment Securities peaked at $5.9 million during Q2 2024, and registered a low of -$8.2 million during Q4 2024.
  • Moreover, its 5-year median value for Gains from Investment Securities was -$464000.0 (2021), whereas its average is -$1.2 million.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first plummeted by 153072.29% in 2021, then surged by 473250.0% in 2023.
  • Recursion Pharmaceuticals' Gains from Investment Securities (Quarter) stood at -$1.2 million in 2021, then plummeted by 313.14% to -$4.8 million in 2022, then grew by 5.84% to -$4.5 million in 2023, then crashed by 82.89% to -$8.2 million in 2024, then soared by 129.68% to $2.4 million in 2025.
  • Its Gains from Investment Securities stands at $2.4 million for Q3 2025, versus -$4.7 million for Q2 2025 and -$4.4 million for Q1 2025.